Cargando…
OR29-06 Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome
Tumor-induced Osteomalacia (TIO) is a rare condition in which excess FGF23 produced by a tumor leads to renal phosphate wasting, impaired 1,25(OH)(2)D synthesis, osteomalacia, fractures, weakness, fatigue, and decreased mobility. In an ongoing open-label Phase 2 study (NCT02304367), 17 adults with T...
Autores principales: | Carpenter, Thomas O, Miller, Paul D, Weber, Thomas J, Peacock, Munro, Insogna, Karl L, Kumar, Rajiv, Luca, Diana, Cimms, Tricia, Roberts, Mary Scott, de Beur, Suzanne Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208350/ http://dx.doi.org/10.1210/jendso/bvaa046.403 |
Ejemplares similares
-
OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome
por: Jan De Beur, Suzanne, et al.
Publicado: (2019) -
OR13-1 Long-Term Burosumab Therapy Provides Sustained Benefit in Patients with Tumor-Induced Osteomalacia: End of Study Findings From the Pivotal Phase 2 Study
por: Carpenter, Thomas, et al.
Publicado: (2022) -
Burosumab for the Treatment of Tumor‐Induced Osteomalacia
por: Jan de Beur, Suzanne M, et al.
Publicado: (2021) -
Reply to: Burosumab for Tumor‐Induced Osteomalacia: not Enough of a Good Thing
por: Jan de Beur, Suzanne M., et al.
Publicado: (2021) -
OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial
por: Perwad, Farzana, et al.
Publicado: (2020)